<DOC>
	<DOCNO>NCT00317785</DOCNO>
	<brief_summary>RATIONALE : Giving total-body irradiation chemotherapy , cyclophosphamide , donor stem cell transplant help stop patient 's immune system reject donor 's stem cell help stop growth cancer abnormal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving immunosuppressive therapy transplant may stop happen . PURPOSE : This phase II trial study well give total-body irradiation together cyclophosphamide work treat patient undergo donor stem cell transplant hematologic cancer disease .</brief_summary>
	<brief_title>Total-Body Irradiation Cyclophosphamide Treating Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate potential efficacy target cyclophosphamide metabolic endpoint give together total-body irradiation , term day 200 nonrelapse mortality , patient hematologic cancer diseases undergo allogeneic hematopoietic stem cell transplantation . Secondary - Determine overall survival patient treat regimen . - Determine rate relapse patient treat regimen . - Determine occurrence sinusoidal obstruction syndrome patient treat regimen . - Determine occurrence acute renal failure patient . - Determine occurrence respiratory failure patient . OUTLINE : - Conditioning regimen : Patients undergo total-body irradiation twice daily day -6 -4 . Patients also receive cyclophosphamide IV 1 hour day -3 IV metabolism-based dose* day -2 . NOTE : *Patients undergo frequent blood sample completion first cyclophosphamide infusion pharmacokinetic study order determine dose second cyclophosphamide infusion . - Allogeneic stem cell transplantation : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive GVHD prophylaxis per attend physician , include one follow regimen : cyclosporine methotrexate ; tacrolimus methotrexate ; tacrolimus mycophenolate mofetil ; sirolimus , tacrolimus , methotrexate ( per GVHD prophylaxis regimen choose patient ) . After completion study treatment , patient follow periodically least 200 day . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematologic cancer disease unlikely respond conventional treatment , include follow : Chronic myelogenous leukemia Acute myeloid leukemia Acute lymphocytic leukemia Myelodysplastic syndrome Lymphoma Patients bulky tumor mass must require additional involvedfield irradiation Planning undergo condition transplantation Seattle Cancer Care Alliance University Washington Medical Center Must HLAmatched donor available No donor mismatch &gt; 1 HLA class I antigen allele Negative antidonor lymphocytotoxic crossmatch PATIENT CHARACTERISTICS : Life expectancy must severely limited disease malignancy No moribund patient Creatinine ≤ 1.2 mg/dL Oxygen saturation room air ≥ 93 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No cirrhosis No hepatic fibrosis bridge No fulminant hepatic failure No acute liver injury No persistent cholestasis No infection require systemic antibiotic antifungal therapy No coronary artery disease No congestive heart failure require therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior hematopoietic stem cell transplantation No prior radiation therapy liver adjacent organ More 30 day since prior cytoreductive chemotherapy patient large body burden tumor cell No concurrent enrollment phase I study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>